CC Logo small

Catheter Connections Secures Three Additional U.S. Patents

– DualCap System™ Core Technology Protected by 17 Patents –

SALT LAKE CITY – October 1, 2015 – Catheter Connections, Inc. (CCI) today announced the
issuance of three additional patents from the United States Patent and Trademark Office covering its
proprietary DualCap System™. DualCap® helps prevent catheter-related bloodstream infections
(CRBSIs), including central line-associated blood stream infections (CLABSIs), to improve patient
safety during intravenous (IV) therapy.

The three newly issued patents add to the core patented technology that comprises the company’s
DualCap System platform. Two of the patents cover the disinfection cap technology designed to
protect the male luer connector at the end of IV tubing. The third patent covers the IV Pole Strips™
that provide convenient bedside delivery of the dark blue cap for the male luer connectors on the IV
tubing end, and the light blue cap for needle-free valves.

“As the leading innovator in this field, the CCI team is dedicated to helping healthcare professionals
improve patient safety by preventing CRBSIs,” said Catheter Connections CEO John P. Shannon.
“Our product enhancements will always be designed to respond to the needs of nurses and other
healthcare professionals.”

CCI continues to add future technological advancements to its current patent estate, which includes
17 patents in the U.S. and several outside of the U.S., that confers broad and comprehensive
intellectual property coverage on the DualCap System.

About Catheter Connections
Headquartered in Salt Lake City, Utah, Catheter Connections, Inc. (CCI) develops and
commercializes innovative vascular access products designed to help protect patients from acquiring
infections during intravenous (IV) infusion therapy. Its proprietary DualCap System™ provides rapid
and ongoing protection against bacterial contamination. Designed by nurses for nurses, the family of
easy-to-use products provides healthcare facilities with a cost-effective, integrated solution for helping
in the fight against IV catheter-related blood stream infections (CRBSIs), including central line-associated
blood stream infections (CLABSIs).

For more information, visit

Media Contact:
Jed Weiner
White Oak Communications, Inc.
(847) 910-1330